Sinopharm Hyundai (600420.SH): Bumetanil injection obtained drug registration certificate

Zhitong Finance App News, Sinopharm Hyundai (600420.SH) issued an announcement. Recently, Sinopharm Group Rongsheng Pharmaceutical Co., Ltd. (hereinafter referred to as Sinopharm Rongsheng), a wholly-owned subsidiary of the company, received the “Drug Registration Certificate” for bumetanib injections approved and issued by the China Drug Administration.

This time, Sinopharm Rongsheng's bumetanib injection obtained a drug registration certificate and was deemed to have passed the consistency evaluation, enriching the company's cardiovascular drug product range, which is conducive to further enhancing the company's comprehensive market competitiveness in related drug use fields, and has a positive impact on the company's future development. The above matters will not have a significant impact on the company's current operating results.